EUCTR2014-004517-84-ES进行中（未招募）1 期
A PHASE II PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND MULTI-CENTRE CLINICAL TRIAL TO ASSESS THE SAFETY OF 0.005 % ESTRIOL VAGINAL GEL IN HORMONE RECEPTOR-POSITIVE POSTMENOPAUSAL WOMEN WITH EARLY STAGE BREAST CANCER IN TREATMENT WITH AROMATASE INHIBITOR IN THE ADJUVANT SETTING.?BLISSAFE Study? - BLISSAFE
ITF Research Pharma S.L.0 个研究点目标入组 61 人开始时间: 2015年1月2日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 61
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Written informed consent prior to beginning specific protocol procedures.
- •2.Patients must have histological confirmation of breast adenocarcinoma with stage I-IIIA, documented at a local pathology department.
- •3.The breast tumors must be estrogen-receptor positive and/or progesterone receptor positive (?1% of stained tumor cells by IHC as determined by the local laboratory) with any HER2 status.
- •4.Postmenopausal status defined as: 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 mIU/ml or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.
- •5.Patient must be receiving the non-steroidal aromatase inhibitors anastrozole or letrozole as breast cancer treatment in the adjuvant setting for a minimum of 6 months.
- •6.Women suffering from moderate to severe vaginal dryness according to the FDA guidelines for drug development in postmenopausal women (Center for Drug Evaluation and Research, CDER Jan 2003). A moderate symptom will be considered if the symptom is present, bothersome and annoying, and a severe symptom will be considered if the symptom is present, bothersome and annoying, and interferes with the normal patient activity.
- •7.Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
- •8.Adequate bone marrow as defined by the following laboratory values:
- •a.Absolute Neutrophil Count (ANC) ? 1.5 x 109/L.
- •b.Platelets (plt) ? 100 x 109/L.
- •c.Hemoglobin (Hgb) ? 10 g/dl.
- •9.Patient has adequate organ function as defined by the following laboratory values:
- •d.Serum creatinine ? 1.5 x ULN.
- •e.Bilirubin ? 1.5 × ULN.
- •f.Alkaline phosphatase ? 2 × ULN.
- •g.AST and ALT ? 2 × ULN.
- •10.Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 50
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •1.Stage IIIB-IV breast cancer or bilateral breast cancer.
- •2.Treatment with any other current anti-tumoral therapy (chemotherapy, anti-Her2?etc) besides the NSAI. Pamidronate or Alendronate are permitted.
- •3.Prior history of other malignancy within 5 years of study entry, aside from non-melanoma skin cancer or carcinoma-in-situ of the uterine cervix adequately treated.
- •4.Postmenopausal uterine bleeding. Vaginal bleeding of unknown etiology.
- •5.Patients with endometrial thickness equal to or greater than 4 mm measured by transvaginal ultrasound.
- •6.Patients who have received any type of vulvovaginal treatment in the 15 days prior to the start of the study.
- •7.Use of any hormone, natural (phytoestrogens) or herbal products for the treatment of menopausal symptoms within the last 6 months.
- •8.Current or previous history of thromboembolic disease or coagulopathies.
- •9.Severe cardiovascular or respiratory diseases in the previous 6 months.
- •10.Renal Impairment.
- •11.Hepatitis B and/or hepatitis C carriers (unless with normal hepatic function).
- •12.Known human immunodeficiency virus infection.
- •13.Known hypersensitivity to NSAI.
- •14.Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
- •15.Previous investigational treatment for any condition or participation in any clinical trial within 4 weeks of inclusion date.
研究者
相似试验
进行中（未招募）
1 期
Clinical trial to evaluate the safety of a vaginal gel containing 0.005% of estriol, in hormone receptor-positive women in menopause with early stage breast cancer in treatment with aromatase inhibitorIn postmenopausal hormone receptor positive breast cancer, treatment with aromatase inhibitors is the most effective and well-studied therapy. Lack of adherence is common due to the side-effectsvaginal dryness and vaginal atrophy. The study will explore the safety of 0.005% estriol vaginal gel in the oncological context, to demostrate that the gel is a safe option to treat the vaginal atrophy caused by AIs, without a significant decline in gonadotropin or increase in systemic estrogen levelsEUCTR2014-004517-84-SEITF Research Pharma S.L.70
已完成
2 期
Safety and Efficacy of GRANEXIN GEL plus Standard of Care in comparison to Standard of Care alone in the Treatment of Diabetic Foot UlcerCTRI/2011/09/001984FirstString Research Inc92
已完成
2 期
To study the Safety and Efficacy of GRANEXIN GEL plus Standard of Care in comparison to Standard of Care alone in the Treatment of Venous Leg UlcerCTRI/2011/09/001985FirstString Research Inc92
进行中（未招募）
1 期
The effect of SJX-653 on Menopausal Hot FlashesEUCTR2019-002281-12-PLSojournix, Inc130
进行中（未招募）
1 期
The effect of SJX-653 on Menopausal Hot FlashesTreatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.MedDRA version: 21.1Level: LLTClassification code 10027311Term: Menopause flushingSystem Organ Class: 100000004872EUCTR2019-002281-12-ESSojournix, Inc